1. Home
  2. RGP vs TLSA Comparison

RGP vs TLSA Comparison

Compare RGP & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Resources Connection Inc.

RGP

Resources Connection Inc.

HOLD

Current Price

$4.71

Market Cap

138.0M

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.16

Market Cap

155.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGP
TLSA
Founded
1996
2013
Country
United States
United Kingdom
Employees
N/A
10
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.0M
155.3M
IPO Year
2000
2017

Fundamental Metrics

Financial Performance
Metric
RGP
TLSA
Price
$4.71
$1.16
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
313.6K
258.1K
Earning Date
04-08-2026
05-04-2026
Dividend Yield
6.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$551,331,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$1.08
52 Week High
$6.07
$2.60

Technical Indicators

Market Signals
Indicator
RGP
TLSA
Relative Strength Index (RSI) 61.95 37.47
Support Level $4.21 N/A
Resistance Level $4.82 $1.54
Average True Range (ATR) 0.22 0.14
MACD 0.01 -0.03
Stochastic Oscillator 89.92 12.99

Price Performance

Historical Comparison
RGP
TLSA

About RGP Resources Connection Inc.

Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: